Last reviewed · How we verify
Brexafemme (IBREXAFUNGERP CITRATE)
Brexafemme (generic name: IBREXAFUNGERP CITRATE) is a Triterpenoid Antifungal Small molecule drug developed by GSK. It is currently FDA-approved (first approved 2021) for Candidiasis of vagina, Vulvovaginal candidiasis.
At a glance
| Generic name | IBREXAFUNGERP CITRATE |
|---|---|
| Sponsor | GSK |
| Drug class | Triterpenoid Antifungal |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2021 |
Approved indications
- Candidiasis of vagina
- Vulvovaginal candidiasis
Common side effects
Key clinical trials
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (PHASE3)
- Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303) (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brexafemme CI brief — competitive landscape report
- Brexafemme updates RSS · CI watch RSS
- GSK portfolio CI
Frequently asked questions about Brexafemme
What is Brexafemme?
Brexafemme (IBREXAFUNGERP CITRATE) is a Triterpenoid Antifungal drug developed by GSK, indicated for Candidiasis of vagina, Vulvovaginal candidiasis.
What is Brexafemme used for?
Brexafemme is indicated for Candidiasis of vagina, Vulvovaginal candidiasis.
Who makes Brexafemme?
Brexafemme is developed and marketed by GSK (see full GSK pipeline at /company/gsk).
What is the generic name of Brexafemme?
IBREXAFUNGERP CITRATE is the generic (nonproprietary) name of Brexafemme.
What drug class is Brexafemme in?
Brexafemme belongs to the Triterpenoid Antifungal class. See all Triterpenoid Antifungal drugs at /class/triterpenoid-antifungal.
When was Brexafemme approved?
Brexafemme was first approved on 2021.
What development phase is Brexafemme in?
Brexafemme is FDA-approved (marketed).
Related
- Drug class: All Triterpenoid Antifungal drugs
- Manufacturer: GSK — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Candidiasis of vagina
- Indication: Drugs for Vulvovaginal candidiasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing